Menarini Asia-Pacific and Pharmacosmos Strengthen Partnership for Iron Deficiency Treatment

Menarini Asia-Pacific has recently strengthened its partnership with Pharmacosmos A/S to exclusively promote MonoFer® (ferric derisomaltose) in Singapore and Malaysia. This collaboration follows their successful joint efforts in Australia. MonoFer® is an advanced intravenous iron treatment designed to effectively combat iron deficiency in various patient populations, facilitating swift iron correction.

Iron deficiency is a widespread concern globally, especially in South and Southeast Asian nations, where it significantly impacts individuals' quality of life, often leading to complications such as anemia. With approvals in over 40 countries, MonoFer® has already positively impacted millions of patients.

The primary goal of this partnership is to introduce innovative iron deficiency therapies to patients in Singapore and Malaysia, where anemia prevalence is notably high among women and the elderly. By capitalizing on Menarini's marketing and distribution proficiency, a larger number of patients will gain access to this crucial treatment.

Menarini Asia-Pacific, a key member of the Menarini Group, is dedicated to enhancing healthcare outcomes in the region by offering a wide array of healthcare solutions. Pharmacosmos Group, renowned for its expertise in carbohydrate chemistry, is focused on developing state-of-the-art treatments for iron deficiency and anemia.

This collaboration marks a significant advancement in expanding treatment options for individuals grappling with iron deficiency in Singapore and Malaysia, ultimately contributing to their improved health and overall well-being.